Reuters logo
BRIEF-Revance announces orphan drug designation of RT002 for the treatment of Cervical Dystonia
November 20, 2017 / 9:26 PM / a month ago

BRIEF-Revance announces orphan drug designation of RT002 for the treatment of Cervical Dystonia

Nov 20 (Reuters) - Revance Therapeutics Inc

* Revance announces orphan drug designation of RT002 for the treatment of Cervical Dystonia

* Revance Therapeutics Inc - ‍U.S. FDA granted orphan drug designation for Co’s product candidate, Daxibotulinumtoxina for injection (RT002)​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below